Orexo Q3 2021 Interim Report
Steady progression on our journey to build a broader and stronger Orexo Q3 2021 highlights · Total net revenues of SEK 145.9 m (150.3) · Net earnings of -52.0 SEK m (-84.9) · EBITDA of SEK -47.4 m (-20.9) · US Pharma segment (ZUBSOLV® US) net revenues of SEK 136.4 m (143.8), in local currency USD 15.8 m (16.2), US Pharma EBIT of SEK 78.5 m (72.4) · Cash flow from operating activities of SEK -79.7 m (-12.9), cash balance of SEK 588.1 m (593.3) · Earnings per share before dilution amounted to -1.51 (-2.45) · Commercial partnership agreement signed with Sober Grid,